Related Experiment Video

Updated: May 15, 2026

Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease
06:25

Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease

Published on: March 29, 2024

Insulin-like growth factor receptor type I as a target for cancer therapy

Nathalie Corvaia1, Alain Beck, Véronique Caussanel

  • 1Centre d'Immunologie Pierre Fabre, Saint Julien-en-Genevois, France. nathalie.corvaia@pierre-fabre.com

Frontiers in Bioscience (Scholar Edition)
|January 2, 2013
PubMed

Insights

Insulin-like growth factor receptor 1 (IGF-IR) is a key target for cancer therapeutics. Developing effective anti-IGF-IR monoclonal antibodies (Mabs) requires identifying biomarkers for patient selection and treatment efficacy.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Insulin-like Growth Factor Receptor 1 (IGF-IR) is a validated target for cancer therapy.
  • Antibodies targeting IGF-IR offer specificity due to homology with the insulin receptor.
  • Despite extensive research, clinical success of anti-IGF-IR therapies remains limited.

Purpose of the Study:

  • To review current knowledge of the IGF-IR axis in oncology.
  • To highlight challenges and strategies for developing anti-IGF-IR monoclonal antibodies (Mabs).
  • To emphasize the need for biomarkers in patient selection for targeted therapies.

Main Methods:

  • Literature review of preclinical and clinical studies on IGF-IR.
  • Analysis of antibody development strategies for IGF-IR.
  • Discussion of biomarker discovery for patient stratification.

Main Results:

  • IGF-IR remains a promising target for novel cancer therapeutics.
  • Antibody-based therapies targeting IGF-IR have shown potential but face challenges in clinical efficacy.
  • Biomarker identification is crucial for selecting patients likely to respond to anti-IGF-IR Mabs and combination treatments.

Conclusions:

  • Further research into IGF-IR signaling is essential for advancing oncology drug development.
  • Development of effective anti-IGF-IR Mabs requires robust biomarker strategies.
  • Targeting the IGF-IR axis holds promise for improving outcomes in specific cancer patient populations.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...